Jonathan Furelid - Scandinavian ChemoTech Head relation

All Insiders . Sweden . 
Stock . Scandinavian ChemoTech AB . Stakeholders . Insider . Jonathan Furelid
CMOTEC-B  SEK 1.74  0.04  2.35%   

Insider

Jonathan Furelid is Head relation of Scandinavian ChemoTech AB
Phone46 1 0218 9300
Webhttps://chemotech.se

Scandinavian ChemoTech Management Efficiency

The company has return on total asset (ROA) of (0.5117) % which means that it has lost $0.5117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1711) %, meaning that it generated substantial loss on money invested by shareholders. Scandinavian ChemoTech's management efficiency ratios could be used to measure how well Scandinavian ChemoTech manages its routine affairs as well as how well it operates its assets and liabilities.
Scandinavian ChemoTech AB has accumulated 53 K in total debt with debt to equity ratio (D/E) of 2.1, implying the company greatly relies on financing operations through barrowing. Scandinavian ChemoTech has a current ratio of 6.95, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Scandinavian ChemoTech until it has trouble settling it off, either with new capital or with free cash flow. So, Scandinavian ChemoTech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scandinavian ChemoTech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scandinavian to invest in growth at high rates of return. When we think about Scandinavian ChemoTech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Dominique TersagoCantargia AB
61
Johan RaudVicore Pharma Holding
N/A
Johanna ChristensenCantargia AB
N/A
Jessica ShullVicore Pharma Holding
N/A
Thoas MDCantargia AB
61
Nina CarlenVicore Pharma Holding
N/A
Ignacio GarciaRibasCantargia AB
N/A
Kicki JohanssonVicore Pharma Holding
65
Anders SandbergAlzinova AB
51
Mats RnngardEnorama Pharma AB
67
Rohit BattaVicore Pharma Holding
N/A
Kristina TorfgardAlzinova AB
N/A
Hakan SkogstromAlzinova AB
62
Johanna GransVicore Pharma Holding
N/A
Adnan DeronicCantargia AB
N/A
Asa MagnussonVicore Pharma Holding
N/A
Per NorlenXintela AB
53
MarcussCantargia AB
N/A
Anders BylockAlzinova AB
N/A
Elin RosendahlVicore Pharma Holding
N/A
CarlJohan MDVicore Pharma Holding
67
Scandinavian ChemoTech AB provides cancer care and pain management solutions. Scandinavian ChemoTech AB is headquartered in Malmo, Sweden. Scandinavian ChemoTech is traded on Stockholm Stock Exchange in Sweden. Scandinavian ChemoTech AB (CMOTEC-B) is traded on Stockholm Exchange in Sweden and employs 6 people.

Management Performance

Return On Equity-1.17
Return On Asset-0.51

Scandinavian ChemoTech Leadership Team

Elected by the shareholders, the Scandinavian ChemoTech's board of directors comprises two types of representatives: Scandinavian ChemoTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scandinavian. The board's role is to monitor Scandinavian ChemoTech's management team and ensure that shareholders' interests are well served. Scandinavian ChemoTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scandinavian ChemoTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Stefan Frick, CEO Founder
Jonathan Furelid, Head relation
Prabhat Rastogi, Chief India
Ann Ohlsson, Head Fin
Suhail Mufti, Local Director

Scandinavian Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Scandinavian ChemoTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.17
Return On Asset-0.51
Operating Margin(48.69) %
Current Valuation68.38 M
Shares Outstanding10.64 M
Shares Owned By Insiders26.03 %
Shares Owned By Institutions3.32 %
Price To Book8.87 X
Price To Sales159.69 X
Revenue49 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in Scandinavian Stock

Scandinavian ChemoTech financial ratios help investors to determine whether Scandinavian Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Scandinavian with respect to the benefits of owning Scandinavian ChemoTech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY